Skip to content
10-Q

Quarterly Report

Prime Medicine, Inc. PRME

0001628280-25-023486

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 131.29M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $34.29M
Current Liabilities Q1 2025 · Dec 31, 2024 $37.96M
Total Liabilities Q1 2025 · Mar 31, 2025 $221.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $144.36M
Current Assets Q1 2025 · Mar 31, 2025 $163.77M
Current Assets Q1 2025 · Dec 31, 2024 $211.89M
Total Assets Q1 2025 · Mar 31, 2025 $328.16M
Total Assets Q1 2025 · Dec 31, 2024 $297.51M
Revenue Q1 2025 · Mar 31, 2025 $1.45M
Revenue Q1 2025 · Mar 31, 2024 $591K
Cash And Equivalents Q1 2025 · Dec 31, 2024 $182.48M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $94.16M
Shares Diluted Q1 2025 · Mar 31, 2024 104.47M sh
Capex Q1 2025 · Mar 31, 2024 $2.32M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$67.71M
Stockholders Equity Q1 2025 · Mar 31, 2024 $243.77M
Stockholders Equity Q1 2025 · Dec 31, 2023 $133.07M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.44
Eps Basic Q1 2025 · Mar 31, 2024 −$0.44
Sga Expense Q1 2025 · Mar 31, 2024 $11.16M
Rd Expense Q1 2025 · Mar 31, 2024 $37.77M
Net Income Q1 2025 · Mar 31, 2024 −$45.76M
Operating Income Q1 2025 · Mar 31, 2024 −$48.34M